Expression of carcinoembryonic antigen cell adhesion molecule 6 oncoprotein in atypical ductal hyperplastic tissues is associated with the development of invasive breast cancer

Clinical Cancer Research

Volumn 12, Issue 15, 2006, Pages 4773-4783

  Poola, Indira ^a   Shokrani, Babok ^a   Bhatnagar, Rakesh ^b   DeWitty, Robert L ^a   Yue, Qingqi ^a   Bonney, George ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; INTERSTITIAL COLLAGENASE; ONCOPROTEIN;

ARTICLE; ATYPICAL DUCTAL HYPERPLASIA; BREAST CANCER; BREAST CARCINOGENESIS; BREAST HYPERPLASIA; CANCER DIAGNOSIS; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BREAST NEOPLASMS; CELL ADHESION MOLECULES; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33748061287     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2286     Document Type: Article

References (37)

1. Allerd DC, Mohsin SK, Fuqua SAW. Histological and biological evolution of human pre-malignant breast disease. Endocr Relat Cancer 2001;8:47-61.
2. Krishnamurthy S, Sneige N. Molecular and biological markers of pre-malignant lesions of human breast. Adv Anat Pathol 2002;9:185-97.
3. Ryan JA, Cody CV. Intraductal epithelial proliferation in the human breast-a comparative study. Cancer J Surg 1962;5:2-8.
4. Karpus CM, Leis HP, Oppenheim A, et al. Relationship of fibrocystic disease to carcinoma of the breast. Ann Surg 1995;162:1-8.
5. Black MM, Barclay TH, Cutler SV, et al. Association of atypical characteristics of benign breast lesions with subsequent risk of breast cancer. Cancer 1972;29: 338-43.
6. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast cancer. N Engl J Med 1985;312:146-51.
7. Dupont WD, Pari FF, Hartman WH. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71:1258-65.
8. London SJ, Conolly JL, Schnitt SJ, et al. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992;267:941-4.
9. Page DL, Dupont WD. Association indicators (histologic and cytologic) of increased breast cancer risk. Breast Cancer Res Treat 1993;28:157-66.
10. Foote FW, Stewart FW. Comparative studies of cancerous versus noncancerous breasts. Ann Surg 1945;121:197-222.
11. Wellings SR, Jenson HM. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975;5:231-43.
12. Poola I, DeWitty RL, Marshallack JJ, et al. Identification of MMP-1 as a putative breast cancer predictive molecular marker by global gene expression analysis. Nat Med 2005;11:481-3.
13. Poola I, Fuqua SAW, DeWitty RL, et al. ERα-negative breast cancer tissues express significant levels of estrogen independent transcription factors, ERβ1 and ERβ5: potential molecular target(s) for chemoprevemion of these cancers. Clin Cancer Res 2005;11:7579-85.
14. Stanners CP, Fuks A. Properties of adhesion mediated by the human CEA family. In: Cell adhesion and communication mediated by CEA family. Basis and clinical perspective. Amsterdam, Hardwood Academic Publishers; 1998, 5; p. 57-79.
15. Ilantzis C, DeMarte L, Screaton RA, Stanners CP. Deregulated expression of human tumor marker CEA family member. CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation. Neoplasia 2002;4:151-63.
16. Jantscheff P, Terracciano L, Lowy A, et al. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol 2003;21:3638-46.
17. Duxbury MS, Ito H, Zinner MJ, et al. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene 2004;23:465-73.
18. Lacroix M, Zammatteo N, Remacle J, Leclercq G. A low density DNA microarray for analysis of markers in breast cancer. Int J Biol Markers 2002;17:5-23.
19. Scholzel S, Zimmermann W, Schwarzkopf G, et al. Carcinoembryonic antigen family members CEA-CAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am J Pathol 2000;156:595-605.
20. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-24.
21. Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian Tamoxifen Study Group. J Natl Cancer Inst 2003; 95:160-5.
22. Tan-Chiu E, Wang J, Constantino JP, et al. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst 2003;95: 302-7.
23. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer lnst 1998;90: 1371-88.
24. Shokar BS, Jarvis C, Sibson DR, et al. Estrogen receptor expression in the normal precancerous breast. J Pathol 1999;188:237-44.
25. Clark RB, Howell H, Potten CS, et al. Disassociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997; 57:4987-91.
26. Chitemere M, Anderson TI, Horn R. p53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Breast Cancer Res Treat 1996;41: 103-9.
27. Stark A, Hulka BS, Jnens S, et al. Her2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 2000;18: 267-74.
28. Blumenthal RD, Hansen HJ, Goldenberg DM. Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA 90) and CEACAM5. Cancer Res 2005;65:8809-17.
29. Duxbury MS, Ito H, Ashley SW, Whang EE. CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in pancreatic adenocarcinoma. Biochem Biophys Res Commun 2004;317:837-43.
30. Chan CHF, Stanners CP. Novel mouse model for carcinoembryonic antigen based therapy. Mol Ther 2004;9:775-85.
31. Chester KA. Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. Cancer Chemother Pharmacol 2000;46:Suppl. S8-12.
32. Xu X. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res 2000;60:4475-84.
33. Soeth E. Controlled ribozyme targeting demonstrates an antiapoptotic effect of carcinoembryonic antigen in HT29 colon cancer cells. Clin Cancer Res 2001;7:2022-30.
34. Wirth T, Soeth E, Czubayko F, et al. Inhibition of endogeneous carcinoembryonic antigen increases the apoptotic rate of colon cancer cells and inhibits metastatic tumor growth. Clin Exp Metastasis 2002; 19:155-60.
35. Marshall J. Carcinoembryonic antigen-based vaccines. Semin Oncol 2003;30:30-6.
36. Marshall JL, Gulley JL, Arlen PM, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005;23:659-61.
37. Moses MA, Clary TM, Hobelk AC, et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and co-stimulatory molecules. Clin Cancer Res 2005; 11:3017-24.